TaiMed Biologics (Taiwan) Today
| 4147 Stock | TWD 85.00 5.10 6.38% |
Performance1 of 100
| Odds Of DistressLess than 20
|
TaiMed Biologics is selling for under 85.00 as of the 26th of November 2024; that is 6.38 percent up since the beginning of the trading day. The stock's lowest day price was 80.8. TaiMed Biologics has about a 20 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for TaiMed Biologics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of September 2024 and ending today, the 26th of November 2024. Click here to learn more.
TaiMed Biologics Inc., a biotechnology company, develops health-care products. The company was founded in 2007 and is based in Taipei City, Taiwan. TAIMED BIOLOGICS operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange. The company has 252.37 M outstanding shares. More on TaiMed Biologics
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
TaiMed Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. TaiMed Biologics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding TaiMed Biologics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman | James Chang |
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
TaiMed Biologics (4147) is traded on Taiwan OTC Exchange in Taiwan and employs 37 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 17.62 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate TaiMed Biologics's market, we take the total number of its shares issued and multiply it by TaiMed Biologics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. TaiMed Biologics operates under Biotechnology sector and is part of Health Care industry. The entity has 252.37 M outstanding shares.
TaiMed Biologics has accumulated about 1.02 B in cash with (211.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.03.
Check TaiMed Biologics Probability Of Bankruptcy
Ownership AllocationTaiMed Biologics shows a total of 252.37 Million outstanding shares. TaiMed Biologics has 17.27 % of its outstanding shares held by insiders and 21.66 % owned by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check TaiMed Ownership Details
TaiMed Biologics Risk Profiles
Although TaiMed Biologics' alpha and beta are two of the key measurements used to evaluate TaiMed Biologics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.13 | |||
| Standard Deviation | 1.62 | |||
| Variance | 2.62 | |||
| Risk Adjusted Performance | 0.0024 |
TaiMed Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in TaiMed Biologics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Fundamental Analysis Now
Fundamental AnalysisView fundamental data based on most recent published financial statements |
| All Next | Launch Module |
TaiMed Biologics Corporate Directors
| MingChing Chen | Independent Director | Profile | |
| LungYeh Cho | Director | Profile | |
| LuPing Chow | Director | Profile | |
| Howard Lee | Independent Director | Profile |
Additional Tools for TaiMed Stock Analysis
When running TaiMed Biologics' price analysis, check to measure TaiMed Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TaiMed Biologics is operating at the current time. Most of TaiMed Biologics' value examination focuses on studying past and present price action to predict the probability of TaiMed Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TaiMed Biologics' price. Additionally, you may evaluate how the addition of TaiMed Biologics to your portfolios can decrease your overall portfolio volatility.